Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Xencor ( (XNCR) ) has provided an announcement.
On May 5, 2025, Xencor announced the resignation of Nancy Valente as Executive Vice President and Chief Development Officer, effective June 6, 2025, with plans for her to continue as a senior advisor. The company reported its first-quarter 2025 financial results, highlighting a net loss reduction compared to the previous year and increased revenues primarily from non-cash royalty and milestone payments. Xencor is advancing its XmAb942 antibody for ulcerative colitis into a Phase 2b study and is preparing a bispecific antibody candidate for Phase 1 trials in 2026. The company expects to maintain significant cash reserves to fund operations into 2028.
Spark’s Take on XNCR Stock
According to Spark, TipRanks’ AI Analyst, XNCR is a Neutral.
Xencor’s overall stock score reflects considerable financial and technical challenges, primarily due to revenue loss and persistent profitability issues. While recent corporate events and strategic board appointments provide some positive outlook, the company’s financial struggles and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on XNCR stock, click here.
More about Xencor
Xencor is a clinical-stage biopharmaceutical company focused on developing engineered antibodies for treating cancer and autoimmune diseases. Utilizing its XmAb technology, Xencor has over 20 candidates in clinical development and collaborates with partners to market multiple XmAb medicines.
Average Trading Volume: 816,333
Technical Sentiment Signal: Sell
Current Market Cap: $601.9M
For an in-depth examination of XNCR stock, go to TipRanks’ Stock Analysis page.